Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fosfomycin Disodium

FDA-approved product (powder, intravenous), marketed as Contepo, Fosfomycin Tromethamine, Monurol.

Registered studies
9
Lab records
7
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Fosfomycin Disodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibacterials; Antiinfectives
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XX01

Repurposing investigation

Fosfomycin Disodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA8.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli0.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae2.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis14.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

9registered studies name this medicine, for any condition. See them below.

Experimental

  • E. coli: measured active in 0 of 1 lab record
  • K. pneumoniae: measured active in 0 of 6 lab records
Open Fosfomycin Disodium in ChEMBL Registered studies below
Show the 7 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-3.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-3.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fosfomycin Disodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections

    NCT07063095 · start 2025-08-25

    Registered record
    Registry ID
    NCT07063095
    Conditions
    Gram Negative Infections; Sepsis and Septic Shock
    Interventions
    Ceftazidime± avibactam with fosfomycin; Ceftazidime± avibactam with placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-08-25
    Completion
    2026-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram Negative Infections; Sepsis and Septic Shock
    InterventionCeftazidime± avibactam with fosfomycin; Ceftazidime± avibactam with placebo
    PhasePhase 3
    Registry statusRecruiting

  • Preoperative Endoscopic Treatment With Fosfomycin and Metronidazole in Patients With Right-sided Colon Cancer and Colon Adenoma (MEFO-trial)

    NCT04312360 · start 2020-01-16

    Registered record
    Registry ID
    NCT04312360
    Conditions
    Right-sided Colon Cancer; Right-sided Colon Adenoma
    Interventions
    therapeutic endoscopy with metronidazole and fosfomycin disodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-01-16
    Completion
    2023-07-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRight-sided Colon Cancer; Right-sided Colon Adenoma
    Interventiontherapeutic endoscopy with metronidazole and fosfomycin disodium
    PhasePhase 2
    Registry statusCompleted

  • Intravenous Fosfomycin Pharmacokinetics Study

    NCT03910673 · start 2019-06-27

    Registered record
    Registry ID
    NCT03910673
    Conditions
    Bacterial Infection; Multiple-drug Resistance; Pathogen Resistance
    Interventions
    Fosfomycin disodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-06-27
    Completion
    2020-12-17
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infection; Multiple-drug Resistance; Pathogen Resistance
    InterventionFosfomycin disodium
    PhasePhase 1
    Registry statusCompleted

  • PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)

    NCT03709914 · start 2018-05-24

    Registered record
    Registry ID
    NCT03709914
    Conditions
    Pediatric ALL
    Interventions
    ZTI-01 100 mg/kg; ZTI-01 75 mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2018-05-24
    Completion
    2026-01-10
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric ALL
    InterventionZTI-01 100 mg/kg; ZTI-01 75 mg/kg
    PhasePhase 1
    Registry statusUnknown

  • 4-way Crossover QT Evaluation in Healthy Subjects

    NCT03709927 · start 2018-01-11

    Registered record
    Registry ID
    NCT03709927
    Conditions
    Cardiac Repolarization in Healthy Subjects
    Interventions
    ZTI-01; Moxifloxacin 400mg; Placebo IV
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-01-11
    Completion
    2018-08-21
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Repolarization in Healthy Subjects
    InterventionZTI-01; Moxifloxacin 400mg; Placebo IV
    PhasePhase 1
    Registry statusCompleted

  • Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients

    NCT03235947 · start 2016-09-07

    Registered record
    Registry ID
    NCT03235947
    Conditions
    Urinary Tract Infection; Asymptomatic Bacteriuria
    Interventions
    Fosfomycin disodium; Trimethoprim / Sulfamethoxazole; Intravenous placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-09-07
    Completion
    2017-11-06
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection; Asymptomatic Bacteriuria
    InterventionFosfomycin disodium; Trimethoprim / Sulfamethoxazole; Intravenous placebo
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

    NCT02753946 · start 2016-04

    Registered record
    Registry ID
    NCT02753946
    Conditions
    Urinary Tract Infection Symptomatic; Acute Pyelonephritis; Urinary Tract Infection Complicated
    Interventions
    ZTI-01; Piperacillin-tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2016-04
    Completion
    2017-05-30
    Enrolment
    465

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection Symptomatic; Acute Pyelonephritis; Urinary Tract Infection Complicated
    InterventionZTI-01; Piperacillin-tazobactam
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects

    NCT02178254 · start 2014-08

    Registered record
    Registry ID
    NCT02178254
    Conditions
    Pseudomonas Infection
    Interventions
    Fosfomycin tromethamine; Fosfomycin disodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-08
    Completion
    2014-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPseudomonas Infection
    InterventionFosfomycin tromethamine; Fosfomycin disodium
    PhasePhase 1
    Registry statusCompleted

  • Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli

    NCT02142751 · start 2014-07

    Registered record
    Registry ID
    NCT02142751
    Conditions
    Infection Due to ESBL Escherichia Coli
    Interventions
    Fosfomycin sodium intravenous; Meropenem intravenous; Ceftriaxone intravenous
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-07
    Completion
    2019-03
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection Due to ESBL Escherichia Coli
    InterventionFosfomycin sodium intravenous; Meropenem intravenous; Ceftriaxone intravenous
    PhasePhase 3
    Registry statusCompleted